stockaxis

Emami Ltd

Quarterly Result - Q1FY25

Emami Ltd

Household & Personal Products

Current

CMP
Rs. 824.35
Rating:
Hold
August 01, 2024

Previous

Rating:
Hold

Stock Info

BSE
531162
NSE
EMAMILTD
Bloomberg
HMN:IN
Reuters
EMAM.NS
Sector
Household & Personal Products
Face Value (Rs)
1
Equity Capital (Rs cr)
44
Mkt Cap (Rs cr)
35096.78
52w H/L (Rs)
844.65 - 417.10
Avg Daily Vol (BSE+NSE)
252,828

Shareholding Pattern

(as on 30-Jun)
%
Promoter
54.84
FIIs
14.02
DIIs
21.61
Public & Others
9.53
Source: Ace equity, stockaxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
13.99
69.64
78.06
Sensex
3.01
9.73
23.18
Source: Ace equity, stockaxis Research

Indexed Stock Performance

Emami Ltd Sensex
Emami Ltd
Source: Ace equity, stockaxis Research

Financial Highlights:

Particulars (Rs. In cr) Q1FY25 Q1FY24 YoY (%) Q4FY24 QoQ (%)
Revenue from Operations 906.00 826.00 10.00% 891.00 2.00%
EBITDA 216.50 190.00 14.00% 211.00 3.00%
EBITDA Margin (%) 23.90% 23.00% 90 bps 23.68% 22 bps
PAT 150.00 137.00 10.00% 147.00 2.00%
EPS (Rs.) 3.50 3.13 12.00% 3.41 3.00%

Source: Company Filings; stockaxis Research

Q1FY25 Result Highlights
Emami reported Q1FY25 earnings better than expectations driven by strong volume growth. Consolidated net sales grew 10% YoY to Rs.906 cr. The domestic business grew 10% YoY, led by 9% volume growth. There was a sequential improvement in demand in the rural market. International business grew 10%and 11% growth in CC terms, driven by double-digit growth in MENA and SAARC regions. The overall oral care category is grown by 10% in 1QFY25.

Harsh summer translated into strong demand for cooling products. Growth was led by Navratna and Dermicool (27%) due to strong summers and was supplemented by 11% growth in Healthcare, 9% growth in 7 Oils in One & 4% in Boroplus. Kesh King (15% de-growth), Pain Management (7% de-growth) & Malegrooming (5% de-growth) continue to remain under pressure Conversely, the severe summer hurt the pain management range (-7% YoY). Kesh King and male grooming dipped 15% and 5% YoY, respectively.

Gross Margins expanded 228 bps to 67.7%. Due to reinvestment in the business and higher ad spends which rose 21% YoY (up 188bps), EBITDA margin saw limited 90bps YoY expansion to 23.9% (in line). MT grew 25% YoY, and e-commerce rose 29% YoY. Both contributed 22% of revenue. PAT grew by 10% YoY to Rs.150 cr which managed to beat estimates.

Key Conference call takeaways

Performance and outlook

  • In Q1FY25, sequential improvement was seen in rural demand.
  • The increase in food inflation will hurt the discretionary consumption.
  • Due to the severe summer, healthy performance was witnessed for the summer products, while sales of non-summer products and out-of-home consumption were hit during the quarter.
  • Company is optimistic about future growth, supported by a favourable economic landscape, forecast of a normal monsoon, anticipated rural market recovery, and government initiatives.
  • MT grew 25% and e-commerce rose 29% YoY in 1QFY25, contributing 11% each in revenue contribution.
  • Domestic volume grew 8.7% in 1QFY25. Excluding the strategic investment (D2C portfolio), volume growth from core business is also more than 7%.
  • The company will only take moderate price increase (1-2%) in FY25.
  • Summer portfolio (Navratna and Dermicool range) contribution in revenue stood at 50%

Cost and Margins

  • GP margin is expanded due to benign raw material prices and price action taken by company.
  • The A&P spending will remain in the range of 18-19% for the full year. Normally it is higher in first quarter (20% of sales in Q1FY25).

Segmental outlook

  • Company launched two extensions for Dermicool, Dermicool her and Dermicool Soap in the modern trade and e-Commerce channels.
  • In the Kesh King brand, Organic Rosemary Oil & Rosemary Shampoo were launched in the ecommerce space.
  • The premium hair fall oil market is seeing subdued demand.
  • Kesh King is a more rural-salient portfolio. With green shoots in rural areas and strategic initiatives taken by Emami, recovery is expected in the range.
  • Kesh King’s annual revenue contribution is over Rs.300 cr vs Rs.230 cr at the time of acquisition. Kesh King shampoo is one-third of the Kesh Ling’s overall portfolio.
  • Emami introduced five new digital-first products: Dia-BTS tonic, DiaBTS tablets, Zandu Neelibhringar Hair Oil, Zandu Ashwagandha 66 (KSM-66) and Zandu Shilajit Gold Plus Resin capsules on the Zandu care portal.
  • In healthcare, OTC & Medico range posted high single digit growth while Zandu care grew strongly led by Digital first portfolio.
  • In male grooming range, Fair and Handsome nature first range of cream and facewash performing well.
  • Pain management range declined 9% in 1QFY25 hurt by extended summer.
  • In Zandu care, the focus is on the online sales. Therefore, pricing is premium than the products available on general trade, however, it is aligned with the competitors.
  • Management guided double-digit growth in healthcare range going forward.
  • The D2C portfolio (The Man company and Brillare) contributes ~ 5-6% in revenue in FY24.
  • The overall oral care category grew by 10% in Q1FY25.
  • HMN expects 5-6% volume growth along with 1-2% value growth in FY25. HMN shall not be aggressive with price hikes in FY25.
  • Margin guidance for current year is 26-27% even as A&P spends are likely to see 50-100 bps increase due to new launch pipeline.
  • The Man Company & Brillare (~8% of revenue, Rs. 225cr in FY24), sales are expected to reach around Rs. 275cr with growth of 20-25%

Outlook & valuation

Emami delivered better than expected earnings for the quarter ended Q1FY25 on the back of higher volume growth. Management remains optimistic about the company’s growth prospects supported by a favourable economic landscape, forecast of a normal monsoon, anticipated rural market recovery, government initiatives, and promising macroeconomic factors, all contributing to a promising outlook for sustained positive performance. We anticipate that the double-digit growth will be aided by the strong summer season, favourable base for the winter season, and rural recovery driven by a normal monsoon, distribution expansion efforts, robust performance in key products. We continue to expect volume growth acceleration in FY25, driven by rural pickup, seasonal tailwinds, aggressive marketing spends, and new launches. At CMP of Rs.812, the stock is trading at 35x FY26E. We maintain HOLD rating on the stock.

Consolidated Financial statements

Profit & Loss statement

Particulars (Rs. In cr) Q1FY25 Q1FY24 YoY (%) Q4FY24 QoQ (%)
Revenue from Operations 906.00 826.00 10.00% 891.00 2.00%
COGS 293.00 286.00 2.00% 305.00 -4.00%
Gross Profit 613.00 540.00 14.00% 586.00 5.00%
Gross Margin (%) 67.66% 65.38% 228 bps 66.00% 166 bps
Employee Benefit expenses 111.00 101.00 10.00% 90.00 23.00%
Other expenses 285.50 249.00 15.00% 285.00 0.00%
EBITDA 216.50 190.00 14.00% 211.00 3.00%
EBITDA Margin (%) 23.90% 23.00% 90 bps 23.68% 22 bps
Depreciation and amortisation expenses 44.00 46.00 -4.00% 48.00 -8.00%
EBIT 172.50 144.00 20.00% 163.00 6.00%
Finance cost 2.00 2.00 0.00% 3.00 -33.00%
Other Income 10.00 8.00 25.00% 11.00 -9.00%
Profit before Share of loss of associates, and Tax 180.50 150.00 20.00% 171.00 6.00%
Share of Loss of associates -2.00 -0.50 -1.57
Profit before Tax and Exceptional Item 178.00 150.00 19.00% 169.43 5.00%
Exceptional item - - -
Profit before Tax 178.00 150.00 19.00% 169.43 5.00%
Tax expenses 28.00 13.00 115.00% 22.48 25.00%
PAT 150.00 137.00 10.00% 147.00 2.00%
EPS (Rs.) 3.50 3.13 12.00% 3.41 3.00%